Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Genomics Licenses Biomarkers from Garvan Institute

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Clinical Genomics today said that it has licensed rights to certain cancer biomarkers from The Garvan Institute of Medical Research.

The Sydney, Australia-based firm said that it has obtained worldwide, exclusive rights to Garvan's cancer-associated methylation DNA biomarkers for the diagnosis and/or treatment of colorectal cancer. Clinical Genomics said that it will evaluate the biomarkers for possible development of diagnostic tests for early detection of colorectal cancer.

"Through this strategic licensing agreement with the Garvan Institute, we have complemented our existing technology portfolio and enhanced our ability to develop next generation products for diagnosing colorectal cancer at the earliest, most treatable stage," Lawrence LaPointe, CEO of Clinical Genomics, said in a statement.

The Garvan Institute, which also is based in Sydney, focuses on genetics research in cancer and metabolic syndromes.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.